Sosei Group Corporation Announces Initiation of Phase III Study for SO-1105 for the Treatment of Oropharyngeal Candidiasis
3/12/2013 10:00:41 AM
More...
|
Sosei Group Corporation: Data at ERS Shows Efficacy of Once-daily COPD Portfolio Versus Comparators, Further Establishes Dual-bronchodilator QVA149
9/4/2012 11:52:42 AM
More...
|
Sosei Group Corporation Announces Successful Completion of Phase I Study for SO-1105 for the Treatment of Oropharyngeal Candidiasis
7/2/2012 9:28:38 AM
More...
|
Sosei Group Corporation Release: Once-daily Seebri® Breezhaler® Receives Positive CHMP Opinion to Treat COPD Patients in the EU
6/25/2012 11:55:44 AM
More...
|
Sosei Group Corporation's QVA149 ILLUMINATE Phase III COPD Study Meets Primary Endpoint and Clarification of Anticipated Timing of US Filings for NVA237 and QVA149
4/24/2012 6:52:33 AM
More...
|
Sosei Group Corporation Release: QVA149 Phase III COPD Studies Met Primary Endpoints
4/2/2012 11:18:22 AM
More...
|
Sosei Group Corporation Announces Private Placement of New Shares by its Subsidiary
3/8/2012 10:33:38 AM
More...
|
Sosei Group Corporation Announces Initiation of Phase I Study for SO-1105
3/8/2012 10:32:34 AM
More...
|
Sosei Group Corporation Release: NVA237 Filed in Europe and Positive Phase III Data at European Respiratory Society Congress
9/27/2011 12:35:31 PM
More...
|
Sosei Group Corporation to Receive Grant from NEDO's FY2011 Innovation Promotion Programme for Development of Innovative Ophthalmic Solutions
8/23/2011 11:06:51 AM
More...
|
|